Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer

Members of a House committee sent FDA Commissioner Robert Califf, MD, a letter urging the agency to take a closer look at some pharma companies’ “alarming practice” of working with the Chinese People’s Liberation Army. (BioSpace)

Regeneron announced that the FDA declined to approve linvoseltamab for relapsed/refractory multiple myeloma at the current time because of manufacturing issues related to a third-party facility.

What can oncologists learn from a “lighthearted” book about cancer? (Oncology News Central)

Galapagos NV announced FDA clearance to launch a phase I/II trial of its autologous CD19 CAR-T cell therapy product candidate GLPG5101 for non-Hodgkin lymphoma using their cell therapy manufacturing platform that aims to reduce CAR T-cell processing time to 7 days.

The U.S. Office of Research Integrity has accused a former cancer researcher at the University of Maryland, whose funded work included 19 NIH grants, of falsifying data in more than a dozen published papers. (Retraction Watch)

Preliminary clinical results suggest the PARP inhibitor olaparib (Lynparza) can achieve responses in certain mutated prostate cancers without the use of hormonal therapy. (Johns Hopkins, JAMA Oncology)

An artificial intelligence program showed potential to improve understanding of the risk of radiation therapy-associated cardiac arrhythmias. (JACC: CardioOncology)

The American Cancer Society and Color Health announced the launch of a pilot program to distribute free at-home colorectal cancer screening kits to people living in rural and other underserved areas.

A meditation technique called “mindful breathing” may help reduce pain and anxiety in patients with cancer. (U.S. News & World Report)

AIM ImmunoTech reported positive findings from a clinical trial evaluating the TLR-3 receptor agonist rintatolimod (Ampligen) in pancreatic cancer.

Do agricultural practices in Iowa contribute to the state’s rising cancer incidence, which is second in the U.S.? (Des Moines Register)

Second-generation androgen-targeting drugs outperform chemotherapy for advanced prostate cancer, but the results depend on the types of mutations that drive a specific patient’s cancer. (Karolinska Institute, Nature Medicine)